Diagnostic Approach in Fetal Coarctation of the Aorta: A Cost-Utility Analysis

被引:22
|
作者
Evers, Patrick D. [1 ]
Ranade, Daksha [2 ,3 ]
Lewin, Mark [1 ]
Arya, Bhawna [1 ]
机构
[1] Univ Washington, Sch Med, Dept Pediat, Div Cardiol, Seattle, WA 98195 USA
[2] Univ Washington, Sch Med, Dept Res Informat, Seattle, WA USA
[3] Seattle Childrens Hosp, Seattle, WA 98105 USA
关键词
Aortic coarctation; Echocardiography; Prenatal; Cost-utility analysis; CONGENITAL HEART-DISEASE; MALFORMATIONS; LIFE; ARCH;
D O I
10.1016/j.echo.2017.01.019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Coarctation of the aorta (CoA) is difficult to diagnose by fetal echocardiogram (F-Echo), often requiring multiple F-Echos during gestation and neonatal echocardiograms (N-Echos) after birth. Furthermore, CoA is the most common ductal-dependent lesion missed on routine physical exam. Objectives: We sought to determine the most cost-effective diagnostic approach in caring for infants in whom an initial F-Echo is concerning for CoA. Methods: Four paradigms for management after initial F-Echocouldnot ruleoutCoAwere compared, witha single paradigm involving additional F-Echos: (1) multiple F-Echos for diagnostic clarity and performance of N-Echo on neonates with remaining high suspicion for CoA on F-Echos (prenatal-multiple), (2) no further F-Echo and performance of N-Echo on neonates with high suspicion for CoA on initial F-Echo (postnatal-selective), (3) no further F-Echo and performance of N-Echo on all neonates (postnatal-all), and (4) no further F-Echo or N-Echo with reliance on routine physical exam to identify afflicted infants (postnatal-none). Decision analysis models were constructed. Probabilities dictating clinical course and costs were calculated using our institution's study population. The utility-state values were derived from existing literature. The measure of effectiveness was quality-adjusted life years. To represent societal perspectives, cost was defined as hospital reimbursement payments. Results: From 2007 to 2014 at our institution, 92 patients were diagnosed with CoA and met the inclusion criteria for this study. These patients presented to care either through prenatal diagnosis (n = 31), postnatal examination findings while clinically well (n = 41), or after clinical deterioration in extremis (n = 20), with one patient subsequently dying. Presenting in extremis was associated with a 20% increase in the cost of their subsequent care and with a 51% increase in length of hospital stay. Postnatal-none was the least effective paradigm but also the least costly, thus forming the baseline model. Of the three other diagnostic approaches modeled, Postnatal-all was the cost-effective paradigm, maximizing utility due to avoidance of high-cost/low-utility disease states such as presentation in extremis and death. Prenatal-multiple was the next most effective but was also the most expensive. Conclusions: Echocardiography is the screening gold standard in avoiding the devastating clinical manifestations of a missed CoA. When a diagnosis of CoA cannot be ruled out on initial F-Echo, the most cost-effective approach is performance of N-Echo on all neonates with no further prenatal evaluation.
引用
收藏
页码:589 / 594
页数:6
相关论文
共 50 条
  • [41] COST-UTILITY ANALYSIS OF EXERCISE FOR THE PREVENTION OF CANCER
    O'Day, K.
    Campbell, D. J.
    VALUE IN HEALTH, 2016, 19 (07) : A740 - A740
  • [42] Cost-utility analysis for endoscopic sinus surgery
    Wang, PC
    Chu, CC
    Liang, SC
    Tai, CJ
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2004, 130 (01) : 31 - 38
  • [43] The treatment of insomnia in the elderly: A cost-utility analysis
    Bell, L
    Tousignant, P
    MEDICAL DECISION MAKING, 1998, 18 (04) : 487 - 487
  • [44] Cost-utility analysis of an implant treatment in dentistry
    Johana Losenická
    Ondřej Gajdoš
    Vojtěch Kamenský
    BMC Oral Health, 21
  • [45] Tracing the diffusion of cost-utility analysis as an innovation
    Sonnad, SS
    Greenberg, D
    Rosen, AB
    Olchanski, NV
    Chapman, R
    Neumann, PJ
    VALUE IN HEALTH, 2004, 7 (03) : 302 - 302
  • [46] COST-UTILITY ANALYSIS OF SIGNAL CONTROL SYSTEMS
    KAY, JL
    MANAGEMENT CONTROLS, 1970, 17 (03): : 48 - 55
  • [47] COST-UTILITY ANALYSIS - WHAT SHOULD BE MEASURED
    RICHARDSON, J
    SOCIAL SCIENCE & MEDICINE, 1994, 39 (01) : 7 - 21
  • [48] Cost-utility analysis of nonalcoholic steatohepatitis screening
    Zhang, Eric
    Wartelle-Bladou, Claire
    Lepanto, Luigi
    Lachaine, Jean
    Cloutier, Guy
    Tang, An
    EUROPEAN RADIOLOGY, 2015, 25 (11) : 3282 - 3294
  • [49] Neonatal Screening: Cost-utility Analysis for Galactosemia
    Hatam, Nahid
    Askarian, Mehrdad
    Shirvani, Samad
    Siavashi, Elham
    IRANIAN JOURNAL OF PUBLIC HEALTH, 2017, 46 (01) : 112 - 119
  • [50] Trastuzumab beyond progression: a cost-utility analysis
    Matter-Walstra, K. W.
    Dedes, K. J.
    Schwenkglenks, M.
    Brauchli, P.
    Szucs, T. D.
    Pestalozzi, B. C.
    ANNALS OF ONCOLOGY, 2010, 21 (11) : 2161 - 2168